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Introduction
e dystrophinopathies are a group of muscle disorders that are caused by mutations in the DMD gene [1] . e DMD gene encodes dystrophin, a glycoprotein that is present principally in muscle cells and forms part of the complex linking the cytoskeleton with the extracellular matrix [2] . Mutations that lead to a complete lack of dystrophin expression tend to cause the more severe Duchenne muscular dystrophy (DMD) phenotype, whereas mutations that lead to an abnormal quality or quantity of dystrophin result in the Becker muscular dystrophy (BMD) [3] . In addition, DMD-related Xlinked dilated cardiomyopathy (DCM) occurs as a result of mutations that lead to a lack of functional dystrophin in cardiac muscles due to altered tissue-speci�c transcription or alternative splicing [4] .
More than 5,000 mutations have been identi�ed in individuals with DMD or BMD [5, 6] . ese pathogenic mutations are highly variable and run the full gamut from deletion of the entire gene, to deletion or duplication of one or more exons, to small deletions or insertions, and to singlebase pair changes. Deletions and duplications account for 60-70% and 5-10%, respectively, of all cases [3] . Sequence variants (point mutations and small indels) are responsible for a further 25-35% of cases [7] . ere are two hotspots for recombination within the gene, one at the 5 ′ end (exons [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] and the other at the distal end (exons 44-53), leading to a cluster of deletions and duplications at these locations 2 ISRN Neurology [8, 9] . As a general rule, mutations that alter the reading frame correlate with DMD, whereas those that preserve the reading frame are associated with BMD [6, 10] .
Molecular testing is useful to con�rm a clinical diagnosis in affected males who are suspected to have a dystrophinopathy based on clinical signs and an elevated serum creatine kinase (CK) level and obviates the need for a muscle biopsy. e identi�cation of the causative mutation in an affected individual also informs genetic counselling for the family and allows carrier and prenatal testing to be performed as appropriate [11] .
We report here the development of a streamlined mutation screening protocol for the DMD gene in order to con�rm a clinical diagnosis of affected males and to clarify the carrier status of female family members. is protocol involves the use of array comparative hybridisation (aCGH) in a primary screen for deletions/duplications, followed by bidirectional sequence analysis if no copy number change is found.
Materials and Methods

Patient Samples.
A group of six individuals with known changes within the DMD gene were selected for the validation of the aCGH and sequencing assays. is group included four male individuals with a con�rmed diagnosis of DMD: two as a result of nonsense mutations in the DMD gene (sequence analysis performed at an overseas laboratory) and two as a result of multiexon deletions (detected in our laboratory by multiplex ligation-dependent probe ampli�cation, MLPA). e �h individual was the pregnant female carrier of a deletion in the DMD gene, who was hoping to have prenatal testing carried out at the appropriate point in her pregnancy. Her initial testing had also been performed using MLPA. e sixth was the deceased proband of a family with multiple female members who wanted to clarify the familial mutation and subsequently proceed to carrier testing. Following his death, twenty years ago, Southern blot analysis of the DMD gene with cDNA probes (performed at an overseas laboratory) had identi�ed a heterozygous duplication involving exons 10 and 11 in DNA extracted from his sister, but this change had never been con�rmed in the proband. e only source of DNA available for this individual was a Guthrie card collected at the time of routine newborn screening.
Following full validation of the aCGH and sequencing procedures, a further eight individuals were analysed. is analysis involved carrier testing of three female family members of the probands who were analysed as part of the validation group, prenatal testing of the male foetus of the female carrier mentioned above, and routine diagnostic testing of four males with a clinical diagnosis of dystrophinopathy.
e twelve peripheral blood EDTA samples and one chorionic villus sample (CVS) were referred to the Diagnostic Genetics section of LabPLUS, Auckland City Hospital, for diagnostic, carrier, or prenatal testing, as appropriate. A portion of the Guthrie card for the �nal individual in the validation group was provided by the National Testing Centre, which administers the collection and storage of these samples. Informed consent for genetic testing was given by each patient, or by the appropriate parent/guardian.
DNA Extraction.
Genomic DNA (gDNA) was extracted from peripheral blood EDTA samples using the Gentra Puregene DNA Extraction kit (Qiagen) and from the Guthrie card using the QIAmp DNA Miniblood Kit (Qiagen). Standard phenol/chloroform extraction followed by ethanol precipitation was used to isolate gDNA from chorionic villus cells.
Primer
Design. e dystrophin gene mRNA sequence of interest was identi�ed through the public UCSC genome browser page at http://genome.ucsc.edu; RefSeq accession number NM_004006.2. We used the primer design program BatchPD to design primers �anking each of the coding exons (1-79) of the DMD gene, including 50 base pairs of the �anking intronic regions (see Table 1 for primer sequences). BatchPD was designed to automate and streamline the primer design process by using the appropriate RefSeq accession number to interface with a range of available online tools and provide a standardised summary output of the most relevant information (such as suitable primer sequences, the genomic coordinates of these primers, and the size of the amplicons produced) [12] . Included in the output is a list of primer sequences that are formatted for easy entry into SNPCheck, the online soware tool available from the National Genetic Reference Laboratory, Manchester (https://ngrl.manchester.ac.uk/SNPCheckV3/snpcheck .htm), which can be used to check the primers for underlying single nucleotide polymorphisms. e primers were tailed with M13 sequences and were synthesised by Integrated DNA Technologies Inc.
Primer designs that failed PCR ampli�cation or produced unsatisfactory ampli�cation results were identi�ed (see Table  1 : highlighted primers) and required redesigns. e redesign process involved returning to the BatchPD results and identifying alternative primer designs. If the sequences of these designs differed enough from the original designs, then the sequences were subjected to SNPCheck and, passing that, the primers were ordered and assessed by PCR ampli�cation. If the alternative primer sequences were too similar to the original primers, then a custom primer design work�ow was undertaken. is work�ow involved using Primer3 soware (http://frodo.wi.mit.edu/primer3/) and the user interface to de�ne the region to be ampli�ed, followed by SNPCheck and, if the primers were found not overlie SNPs, then PCR evaluation. In the case of exon 68 that contains a repetitive sequence immediately 3 ′ of the splice donor site, a reverse sequencing primer was designed using Primer 3 soware (see Table 1 ). 
PCR. PCR was
Primers in use
Primers designed via BatchPD Exon Forward  Reverse  Forward  Reverse  1  TTGGGATCACTCACTTTCCC  AAGAAATCATGTGTTTAGTTCTATCG TTGGGATCACTCACTTTCCC  AAGAAATCATGTGTTTAGTTCTATCG  2  CCCCAAACCAGCATCACTC  TGCACAGCTAAAATAAAATGACAC  CCCCAAACCAGCATCACTC  TGCACAGCTAAAATAAAATGACAC  3  TTTCAAAAGGGGATAATCGTG  TTGCTGTTTCAATCAGTACCTAGTC  TTTCAAAAGGGGATAATCGTG  TTGCTGTTTCAATCAGTACCTAGTC  4  GGTTTCATTTCTAGTAGATTGTCGG  AGCCCTCACTCAAACATGAAG  GGTTTCATTTCTAGTAGATTGTCGG  AGCCCTCACTCAAACATGAAG  5  TTGCAACTAGGCATTTGGTC  CACATTTGTTTCACACGTCAAG  TTGCAACTAGGCATTTGGTC  CACATTTGTTTCACACGTCAAG  6  TTGGCCCTAAAATTTCTATTTATCAC TGGAACGTTAGATCAATGTGG  TTGGCCCTAAAATTTCTATTTATCAC TGGAACGTTAGATCAATGTGG  7  TTCTGGGCTCAAAGGATCTG  GCTCCATCCATAGGGCATAC  TTCTGGGCTCAAAGGATCTG  GCTCCATCCATAGGGCATAC  8  TTTTAGGCCTCATTCTCATGTTC  TGAAGCAAAATTGAAAAGGTTTAG  TTTTAGGCCTCATTCTCATGTTC  TGAAGCAAAATTGAAAAGGTTTAG  9  TTCTACCATGTTGGAAAGTAGTCC  CGAGGAGATAAAAGGCACTG  TTCTACCATGTTGGAAAGTAGTCC  CGAGGAGATAAAAGGCACTG  10  TTCGATTCATCATTTAATGTACTGG  CAAGGATGTAAGAGAGTAATTGAGG  TTCGATTCATCATTTAATGTACTGG  CAAGGATGTAAGAGAGTAATTGAGG  11  CAAAACCACACCGATTTACC  GGGAACAAACTGAGAATCGTAAC  CAAAACCACACCGATTTACC  GGGAACAAACTGAGAATCGTAAC  12 GCAAATGCAGGAAACTATCAGA TGGAAATTGCCAAGAAATACC  GATCATTTCTTTCAGTCTGTGGG  TGGAAATTGCCAAGAAATACC  21  TTAAGCTAAACTTGCCTTACTGC  TACCTTCTGGATTTCCCCAC  TTAAGCTAAACTTGCCTTACTGC  TACCTTCTGGATTTCCCCAC  22  GGAAAACATGGCAAAGTGTG  TGCTCAATGGGCAAACTACC  GGAAAACATGGCAAAGTGTG  TGCTCAATGGGCAAACTACC  23  CATCTACTTTGTTTACATGTTTGAATC AAGATGCTGAAGGTCAAATGC  CATCTACTTTGTTTACATGTTTGAATC AAGATGCTGAAGGTCAAATGC  24  TGGGCCTGTGTTTAGACATAAC  GGGAGAGGAGAGCAAAATCC  TGGGCCTGTGTTTAGACATAAC  GGGAGAGGAGAGCAAAATCC  25  TGCCATCAGTCCCAATTTTAC  CGGTGAAGGGAGACATTAGG  TGCCATCAGTCCCAATTTTAC  CGGTGAAGGGAGACATTAGG  26  TCTGATCCCCATGAGTTATTTTC  TCTTAGAACCAGGAAAGAGCAG  TCTGATCCCCATGAGTTATTTTC  TCTTAGAACCAGGAAAGAGCAG  27  TCTAACTGGGATGTTGTGAGAAAG  GCCAAAGTTGTTTTGCACTG  TCTAACTGGGATGTTGTGAGAAAG  GCCAAAGTTGTTTTGCACTG  28  TGCATTTTGAATTACCTGCTAC  CTCTTGGGTTGTTTTCTTTGG  TGCATTTTGAATTACCTGCTAC  CTCTTGGGTTGTTTTCTTTGG  29  CAAGTTTTAAGTTCTCAGTCCGC  CAGTGTCTGGCATTGGATTG  CAAGTTTTAAGTTCTCAGTCCGC  CAGTGTCTGGCATTGGATTG  30  AAAAGGTGATTGTGGAAGAGTC  CAAATCAGTGAATCAAAACAACC  AAAAGGTGATTGTGGAAGAGTC  CAAATCAGTGAATCAAAACAACC  31  GGTGGTTGAGGAGAGTTTCTG  TGTCCTCAAATCCAATCTTGC  GGTGGTTGAGGAGAGTTTCTG  TGTCCTCAAATCCAATCTTGC  32  CCAGTTATTGTTTGAAAGGCAAA  AATGAGGAAAGTCAAGGGGTA  No Results Returned  No Results Returned  33  TGCAAAAGCTAGATATTGACCAC  CTGAATAAGCAGAGCCTCACTG  TGCAAAAGCTAGATATTGACCAC  CTGAATAAGCAGAGCCTCACTG  34  TGTCATCTGCCCTAGACAGTTT  GTTCAAAATAACCTTCAGTGATATAGG ACAAACGATGTCATCTGCCC  CATGGTCCTGAAAAGCACAG  35  AGGTCAATGCTCTCCTTTTCA  CTCGTGACAGAGAAGGGTGT  CAGAAAGCCGTTTCATAAGC  TTTTCAAACACAGAATTGTTACTGG  36  TGACCAGTAACAATTCTGTGTTTG  CTGAACGGAGTTTACATTGGG  TGACCAGTAACAATTCTGTGTTTG  CTGAACGGAGTTTACATTGGG  37  GCTCACTCGCTCTGTTTGG  AGAGTACTGCGCAACCTTCG  GCTCACTCGCTCTGTTTGG  AGAGTACTGCGCAACCTTCG  38  AGTTTAGCAACAGGAGGTTGAA  TCATTCACACTTTTATCACAACCA  AATGCATGTGATTAGTTTAGCAAC  TGTGCTCTGAAAATTCAGTTGG  39  TTTTGAAACCTCAAGTACCAAATG  CCATAACTTTTAAGCAACACATCG  TGGGAGGAAACTTATTTTGAAAC  CCATAACTTTTAAGCAACACATCG  40  AATAACTGCAGCCAGAAGTGC  GAAGTCGTCCATATACCGATAAGTC  AATAACTGCAGCCAGAAGTGC  GAAGTCGTCCATATACCGATAAGTC  41 CTTGCAAGTCGGTTGATGTG  TGAGGGAAACCACTCACTTTC  CTTGCAAGTCGGTTGATGTG  TGAGGGAAACCACTCACTTTC  42 TGGAGGAGGTTTCACTGTTAGG  ATTTAAGTCAATTGTTCTGGCAC  TGGAGGAGGTTTCACTGTTAGG  ATTTAAGTCAATTGTTCTGGCAC  43 CACCATTTGCTACCTTTGGG  AATAAATTCTACAGTTCCCTGAAAAC CACCATTTGCTACCTTTGGG  CTGAAATAAATTCTACAGTTCCCTG  44 GCAAATGCAGGAAACTATCAGA  TCACCCTTCAGAACCTGATCTT  TGCAACCTTCCATTTAAAATCAG  TTCCATCACCCTTCAGAACC  45 TTTCTTTGCCAGTACAACTGC  TTAGTGCCTTTCACCCTGC  TTTCTTTGCCAGTACAACTGC  TTAGTGCCTTTCACCCTGC  46 AAATTGCCATGTTTGTGTCC  TAATGGGCAGAAAACCAATG  ATGTTTGTGTCCCAGTTTGC  TAATGGGCAGAAAACCAATG  47 CAAGGTAGTTGGAATTGTGCTG  ACATACCAGCCTCCTCCCC  CAAGGTAGTTGGAATTGTGCTG  ACATACCAGCCTCCTCCCC  48 ATTTTGGCTTATGCCTTGAG  aATGATACCAAATGAGAAAATTCAGTG ATTTTGGCTTATGCCTTGAG  TGATACCAAATGAGAAAATTCAGTG  49 AAATTGATCTGCAATACATGTGG  TTTCACTGATTATAAATAGTCCACGTC AAATTGATCTGCAATACATGTGG  TTTCACTGATTATAAATAGTCCACGTC  50 TTCACCAAATGGATTAAGATGTTC  AGCTAGAGCCAAAGAGAATGG  TTCACCAAATGGATTAAGATGTTC  TTTTCTCTCTCACCCAGTCATC  51 TTGGCTCTTTAGCTTGTGTTTC  CTGGTGGGAAATGGTCTAGG  TTGGCTCTTTAGCTTGTGTTTC  CTGGTGGGAAATGGTCTAGG  52 AAGTGTTTTGGCTGGTCTCAC  AAAAGGTAACATTATGGACTGAAAATC AAGTGTTTTGGCTGGTCTCAC  AAAAGGTAACATTATGGACTGAAAATC  53 AAAATGTCTCCTCCAGACTAGCA  CAGCTTTAACGTGATTTTCTGTT  AACATAAATGTGAGATAACGTTTGG  TTCAGCTTTAACGTGATTTTCTG  54 ACGAAGTATTTTAAGACACTCCAAC  CAGTTTCACCACCCCATTATTAC  ACGAAGTATTTTAAGACACTCCAAC  CAGTTTCACCACCCCATTATTAC  55 TTGTTGCTTAAAGGAAGAGCTG  TCCTCCTTGTCCAAATACCG  TTGTTGCTTAAAGGAAGAGCTG  TCCTCCTTGTCCAAATACCG  56 TCCAAATTCACATTCATCGC  CCAGTTACTTGTGCTAAGACAATGAG TCCAAATTCACATTCATCGC  CCAGTTACTTGTGCTAAGACAATGAG  57 TTTCAATGGAATTGTTAGAATCATC  AAAATAGTCACTGGATTACTATGTGC TTTCAATGGAATTGTTAGAATCATC  AAAATAGTCACTGGATTACTATGTGC  58 ACAAGTTCTGAGCACCCAGG  TCCGTCACCACTGATCCTTC  ACAAGTTCTGAGCACCCAGG  TCCGTCACCACTGATCCTTC  59 AAAAGCCGTTAATCAGTAGGTTAC  TTGTGGGAAGATAACACTGCAC  AAAAGCCGTTAATCAGTAGGTTAC  TTGTGGGAAGATAACACTGCAC  60 ACTGGCACTGCACCCTAAAG  CCTATCCTCACAAATATTACCATGAAC ACTGGCACTGCACCCTAAAG  CCTATCCTCACAAATATTACCATGAAC  61 CGAGTCTGGAATACTATATACGGTAAG CAGGATGATTTATGCTTCTACTGC  CGAGTCTGGAATACTATATACGGTAAG TTGGCCTTCCTCTTCCTAAC  62 TGTTGTCTTTCCTGTTTGCG  TAGGCCAGGCTAATGTCGC  TGTTGTCTTTCCTGTTTGCG  TAGGCCAGGCTAATGTCGC  63 GCGCTTTGAAATAAAGATTCC  GGTCACCTGTCATTTAACTTGGA  ATTCCGAATGGTTCAAAAGC  CACCCTTGAAACAATCTAGTGATG  64 GTTATTGGCAAATCACTGGG  TGACAGCTGTTTCTCCCCTC  GTTATTGGCAAATCACTGGG  TGACAGCTGTTTCTCCCCTC  65 GGACACTGAAAGGAAGGTTTTAC  TGTACGCTAAGCCTCCTGTG  GGACACTGAAAGGAAGGTTTTAC  TGTACGCTAAGCCTCCTGTG  66 AAGTGTTTACCCTCTAGGAAAGG  TCATTTCCCATCTAGAACTAGGG  AAGTGTTTACCCTCTAGGAAAGG  TCATTTCCCATCTAGAACTAGGG  67 TTGCTACTGGAATTGAGTTGG  AGAAAACGAAGCTCTGTGGG  TTGCTACTGGAATTGAGTTGG  AGAAAACGAAGCTCTGTGGG  68 TGCCTTCTTTCCTTTCATCC  CTAACAGCAACTGGCACAGG  TGCCTTCTTTCCTTTCATCC  CTAACAGCAACTGGCACAGG  69 TTCTTTGGGAATTTGATTCG  CAGGCTGGCGTCAAACTTAC  TTCTTTGGGAATTTGATTCG  AAAACTGAAATTTATCCCAGGTG  70 GGGCAGAAGACTGGAGTGG  GCTGAGAGGAGTTCAAATATACATC  GGGCAGAAGACTGGAGTGG  GCTGAGAGGAGTTCAAATATACATC  71 TTTTGCGGCTGAGTTTGC  AGAACCAAGCGAGCGAATG  TTTTGCGGCTGAGTTTGC  AGAACCAAGCGAGCGAATG  72 TGTATAACATAACTGTGTGGTGGG  GGAATCAGACAAGTTTGGGG  TGTATAACATAACTGTGTGGTGGG  GGAATCAGACAAGTTTGGGG  73 CAGGAATGTTCGATTAGGTCTTG  TGTGCTATCCTACCTCTAAATCCC  CAGGAATGTTCGATTAGGTCTTG  TGTGCTATCCTACCTCTAAATCCC  74 TGGTAGATCACAACCTCAGCA  TGCACTCTGCATACCAATGA  CCCAAAGCAAAATAAGGGG  AAGATTCCTGGCACTTTTCTATG  75 CTGTTCTTCGGTGGCAGTC  AAATCCCATCTCTCTCCTCAC  TTTGCTTGCTGTTCTTCGG  TCACTTTGCAGGCACATACC  76 AAAATTTATGAGTCCTGAGTGTGTATC ACGGCCAAATATTCATGTCC  AAAATTTATGAGTCCTGAGTGTGTATC ACGGCCAAATATTCATGTCC  77 AATCATGGCCCTTTAATATCTG  GGGTAGGGAAGCGAGTGG  AATCATGGCCCTTTAATATCTG  GGGTAGGGAAGCGAGTGG  78 TGGTAAAAGAAGCAAATTGGTATG  GCTGCAAGTGGAGAGGTGAC  TGGTAAAAGAAGCAAATTGGTATG  GCTGCAAGTGGAGAGGTGAC  79 GGAATGATTTCCCAAATGGC  TCTGCTCCTTCTTCATCTGTC  TTCCCAAATGGCAAAGAAAC  TCTGCTCCTTCTTCATCTGTC Internal reverse sequencing primer: 68_R1 ggttcctaatacctgaatccaatg. Key: BatchPD alternative design (shown in blue); Custom primer re-design (shown in red).
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v3.0 (Applied Biosystems Ltd.). 5 L of sequenced product was puri�ed using the BigDye XTerminator Puri�cation Kit (Applied Biosystems Ltd.). Puri�ed product was then subjected to capillary electrophoresis using the Applied Biosystems model 3130xl Genetic Analyzer. e analysis of sequence traces was performed using Variant Reporter v1.1 (Applied Biosystems). Genebank NM_004006.2 was used as the reference sequence, with cDNA number + 1 corresponding to the A of the translation initiation codon (codon 1). Variant Reporter uses advanced algorithms and quality metrics to automate the detection of variants and to streamline the analysis process.
Dosage Analysis.
A Roche NimbleGen 12x135K Custom CGH Array was used for dosage analysis. is bespoke CGH array has been designed to interrogate the coding regions of sixty-six genes of interest to our laboratory [13] .
Two hundred and �y nanograms of gDNA were processed according to the manufacturer's instructions (NimbleGen Array User's Guide: CGH and CNV Arrays v6.0; http://www.nimblegen.com). In brief, extracted gDNA from samples and Promega controls was denatured in the presence of a Cy3-(test-) or Cy5-(control-) labelled random primers and incubated with the Klenow fragment of DNA polymerase, together with dNTPs (5 mM of each dNTP), at 37 ∘ C for 2 hours. e reaction was terminated by the addition of 0.5 M EDTA (21.5 L), prior to isopropanol precipitation and ethanol washing. Following quanti�cation, the test and sex-matched control samples were combined in equimolar amounts and applied to one of the twelve arrays on the microarray slide. Hybridisation was carried out in a Roche NimbleGen Hybridisation Chamber for a period of 48 hours. Slides were washed and scanned using a NimbleGen MS 200 Microarray Scanner. Array image �les (.tif) produced by the MS 200 Data Collection Soware were imported into DEVA v1.2.1 (Roche NimbleGen Inc.) for analysis. Each genomic region exhibiting a copy number change within the DMD gene was examined using the UCSC genome browser (http://genome.ucsc.edu) to determine the location and signi�cance of the change. Data was �ltered using a log 2 ratio threshold of less than −0.4 over 6 probes for a deletion and greater than 0.4 over 15 probes for a duplication.
Results
Validation of Known Mutations.
We developed a streamlined mutation-screening protocol for the DMD gene. is involved the use of a bespoke CGH array for the deletion/duplication analysis followed, if necessary, by sequence analysis for the detection of point mutations and small indels. As part of the sequencing pipeline, we used a new bioinformatic tool, BatchPD, for efficient primer design. BatchPD successfully designed primers to amplify all coding exons of the DMD gene under the same PCR conditions and the quality of the double-stranded sequence produced was consistently high.
In order to validate the screening protocol, we analysed six patients with known mutations in the DMD gene. We were able to accurately identify the known changes in all six patients (patients 1-6, Table 2 and Figure 1 ), including detection of the familial duplication in the individual for whom the only remaining source of DNA was an archived Guthrie card.
Additional Analysis.
Four males with a clinical diagnosis of dystrophinopathy were referred for routine diagnostic testing. Patient 8 had previously undergone multiplex PCR [3] for deletions several years earlier and gDNA had more recently been sent away for full sequence analysis; both of these assays were normal. Array CGH revealed a duplication of exon 12 of the DMD gene. Further analysis (using the Reading-frame Checker, available online at http://www.dmd.nl/) predicted that this duplication would be in frame, which is consistent with the observed BMD phenotype. Array CGH also identi�ed a mutation in two of the remaining three patients with a clinical diagnosis of the Duchenne muscular dystrophy. An out-of-frame deletion of exons 45-48 (inclusive) was detected in patient 9. A deletion of six probes was identi�ed in patient 10. is intraexonic deletion was at the lower limit of the size threshold for analysis and involved a small portion of exon 37 only. Sequence analysis of exon 37 con�rmed a hemizygous deletion of 11 base pairs within the exon, c.5199_5209del (p.r1734SerfsX10) (Figure 1 ). Although this mutation has not, to the best of our knowledge, been reported in the literature or in mutation databases, it results in premature termination of translation and truncation of the protein and is therefore consistent with the clinical diagnosis of DMD. No mutations were identi�ed using the combination of dosage and sequence analysis for the remaining patient (patient 11).
DNA extracted from a CVS from patient 5 was received at 11 weeks' gestation. A rapid aneuscreen indicated that the foetus (patient 7) was male, so prenatal BMD testing was requested. Following exclusion of maternal cell contamination, aCGH was performed. e familial deletion of exons 45-47 (inclusive) was identi�ed in the foetus and the decision was made to terminate the pregnancy.
e �nal three patients analysed were referred for carrier testing. e familial deletion was identi�ed in two of the three. e duplication previously identi�ed in the affected son of the third individual was not detected on screening of her gDNA, but germline mosaicism could not be excluded.
Discussion
e current European Molecular Genetics Quality Network (EMQN) Best Practice Guidelines on molecular diagnostics in the Duchenne/Becker muscular dystrophies recommend an initial screen for deletions and duplications, followed by a screen for point mutations if the clinical diagnosis is certain but a deletion/duplication has not been found [11] . It is acknowledged by the EMQN group that the approach used in different centres may vary depending on the availability of tests and facilities, as well as economic factors [11] . e DMD gene is the largest human gene yet described, comprised of 79 coding exons and 8 tissuespeci�c promoters distributed across approximately 2.2 Mb Reverse trace patient 1 of genomic sequence [7] . Given the large size of the gene, it has historically been challenging for both technical and �nancial reasons to perform full sequence analysis [14] . As a consequence, numerous methods have been used to scan the DMD gene for point mutations and small indels, including single-strand conformation polymorphism [15] , denaturing high performance liquid chromatography [14] , the protein truncation test [16] , and high-resolution melting curve analysis [17] . Although these mutation scanning methods are a low-cost alternative to sequencing and, therefore, may be more accessible to a small laboratory, the cost of sequencing has reduced appreciably over the last few years and it is now more efficient and cost-effective to perform full sequence analysis as the principle technique. e process of designing suitable primers and optimising the PCR conditions for a sequencing assay can be very labour intensive, and the effort required increases as the size of the gene and number of exons increases. We employed a new primer design programme, BatchPD, to design primers which would allow us to amplify all 79 coding exons of the DMD gene under a single set of PCR conditions. As part of the validation process, the developers of the BatchPD programme designed primers for all 9000 human RefSeq genes, and these primers (as well as the source code for the programme) are freely available online [12] . We found that the use of BatchPD radically reduced the amount of time required to design the primers, and the optimisation process was simple, merely requiring a trial of the primers with and without GC-Rich solution (Roche Diagnostics Ltd.). In addition, as Next Generation Sequencing platforms become more affordable and accessible, it will be possible to retro�t these M13-tailed primers with user-de�ned custom tails, allowing an easy transition from capillary-based to next generation techniques.
Array CGH has recently been recognised as a superior method to the other most widely used dosage technique, MLPA [13, [18] [19] [20] [21] [22] . Compared to MLPA, aCGH allows the interrogation of intronic as well as exonic regions; hence, breakpoints can be mapped more accurately [11] . It can also be used to characterise some inversions and complex rearrangements, thereby offering a slightly higher mutation detection rate compared to MLPA and other purely exonfocused dosage assays [18, 19] . e aCGH process eliminates the risk of false positives that can occur as a result of polymorphisms under primer binding sites [11] . is risk is inherent in all PCR-based techniques and necessitates con�rmation of single exon changes by a second technique or using a different set of primers [11] . e array design we report here is particularly cost effective, since twelve patients can be tested simultaneously for copy number changes in a range of genes, allowing efficient batching of patient samples. e overlapping probes tiling the exons in this array also mean that exceptionally high resolution can be achieved. Using this bespoke CGH array, we were able to con�dently detect the full spectrum of dosage changes responsible for DMD and BMD: deletions and duplications involving multiple exons, single exon changes, and even an intraexonic deletion of only 11 base pairs.
Conclusions
In summary, the DMD gene testing protocol we report here is one that meets current best practice guidelines and can be implemented in a small diagnostic laboratory. Each of the techniques is robust and cost effective and allows for a comprehensive analysis of gDNA extracted from a range of sample types, including peripheral blood, chorionic villus tissue, and dried blood spots. e pipeline of dosage analysis using aCGH followed by full sequence analysis will detect mutations in approximately 98% of patients with the Duchenne or the Becker muscular dystrophy [11] . For the remaining 2% of patients, it is likely that a more complex rearrangement or deep intronic variant is involved, and either an RNA-based method or whole genome sequencing will be required.
